Reports Q1 revenue $96.7M, consensus $93.64M. am pleased with our first quarter financial results, steered by solid execution across both software and services,” said William F. Feehery, Chief Executive Officer. “To date, the strategic investments in additional software capabilities and commercial expansion have progressed on plan, and customer interest for Certara’s products and services remains high. Certara is well positioned to grow in 2024 as biosimulation becomes more widely used across the drug development industry.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT: